Care este prețul pentru RepliCel Life Sciences Inc. (RP)

Prețul pentru RepliCel Life Sciences Inc. (RP) este $0.01100905

Care este capitalizarea de piață pentru RepliCel Life Sciences Inc. (RP)

Capitalizarea de piață pentru RepliCel Life Sciences Inc. (RP) este $810.02K

RepliCel Life Sciences Inc. (RP) Preț și Capitalizare de Piață

Headquartered in Vancouver, Canada, RepliCel Life Sciences Inc. is a regenerative medicine company dedicated to developing innovative autologous cell therapies. These treatments are designed to correct functional cellular deficiencies by harnessing a patient's own cells. The process involves isolating cells from harvested tissues, significantly expanding them in a controlled laboratory environment, and subsequently applying them therapeutically. The company's developmental portfolio includes several key product candidates: RCT-01 targets chronic tendinosis, RCS-01 addresses aging and sun-damaged skin, and RCH-01 is aimed at treating hair loss. Additionally, RepliCel is advancing RCI-02, a specialized dermal injection device. RepliCel has established significant strategic alliances. It holds a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. to establish a clinical research program and facilitate the commercialization of RCS-01 and RCT-01. A similar collaboration exists with Shiseido Company, Limited, focusing on the clinical research program for RCH-01. Furthermore, the company is engaged in a research project agreement with the University of British Columbia, contributing to the creation of a comprehensive hair follicle cell data map.

Prețul pentru RP	Activul B	Capitalizarea de piață a B	Rezultate
$74,446.08 $810.02K	NVDA	$5.478T	+676,225,936.11%
$60,856.42 $810.02K	AAPL	$4.478T	+552,785,093.55%
$56,881.11 $810.02K	GOOG	$4.185T	+516,675,685.74%
$50,347.50 $810.02K	MSFT	$3.704T	+457,328,062.74%
$38,618.82 $810.02K	AMZN	$2.841T	+350,791,388.47%

Prețul pentru RP

Activul B

Capitalizarea de piață a B

Rezultate

$74,446.08 $810.02K